Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma

• Main Authors: A. N. Shoushtari, J. Landa, D. Kuk, A. Sanchez, B. Lala, N. Schmidt, C. Okoli, P. Chi, M. A. Dickson, M. M. Gounder, M. L. Keohan, A. M. Crago, W. D. Tap, S. P. D’Angelo
• Format: Article
• Language: English
• Published: Hindawi Limited 2016-01-01
• Series: Sarcoma
• Online Access: http://dx.doi.org/10.1155/2016/3547497

Background. Leiomyosarcomas (LMS) represent a heterogeneous subset of soft tissue sarcomas. Factors influencing prognosis for patients with metastatic extrauterine LMS (euLMS) are not well described. Limited data are available regarding responses to systemic therapy. Methods. We collected clinical and pathologic information for all patients with metastatic euLMS seen at Memorial Sloan Kettering Cancer Center between 1989 and 2012. Objective responses to first-line therapy were analyzed for a subset of patients with available baseline and on-treatment imaging using RECIST 1.1. Results. 215 patients with metastatic euLMS had a median overall survival (OS) of 2.6 years from the time of metastasis. Older age, male sex, and ≥3 initial sites of metastasis were associated with worse OS on multivariate analysis. Objective response rate (ORR) in N=113 was 19% overall and 25%, 26%, and 25% for gemcitabine, gemcitabine plus docetaxel, and anthracycline-alkylator combinations. Patients whose tumors objectively responded to first-line therapy had a lower risk of death versus those who did not (Hazard Ratio 0.46; 95% CI: 0.26–0.79, p=0.005). Conclusions. Anthracycline- and gemcitabine-based regimens have similar activity in this cohort of euLMS. Prognostic factors for OS include older age, male sex, and ≥3 initial sites.